Published in Neth Heart J on January 01, 2007
One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. Neth Heart J (2010) 0.75
Late stent thrombosis associated with heavy exercise. Tex Heart Inst J (2009) 0.75
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost (2003) 1.97
Aspirin and clopidogrel resistance. Mayo Clin Proc (2006) 1.52
Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med (2006) 1.43
Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant (1998) 0.96
Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet (2000) 3.71
Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation (2001) 3.03
17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation (2001) 2.39
Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation (2001) 2.11
Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med (2001) 1.91
Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Neth Heart J (2014) 1.85
Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J (2011) 1.68
The human adult cardiomyocyte phenotype. Cardiovasc Res (2003) 1.54
A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty. Am Heart J (2000) 1.54
Transgenic myocardial overexpression of fibroblast growth factor-1 increases coronary artery density and branching. Circ Res (2000) 1.54
Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol (1999) 1.54
Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth Heart J (2008) 1.51
Unrecognised myocardial infarction in subjects at high vascular risk: prevalence and determinants. Heart (2009) 1.45
A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol (2013) 1.43
Preservation of left ventricular function and attenuation of remodeling after transplantation of human epicardium-derived cells into the infarcted mouse heart. Circulation (2007) 1.42
Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat (2002) 1.38
17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res (1999) 1.27
Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation (2000) 1.19
Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation (2000) 1.18
Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting? J Am Coll Cardiol (2001) 1.16
Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. Neth Heart J (2008) 1.16
Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular function. J Interv Card Electrophysiol (2000) 1.15
Mouse electrocardiography: an interval of thirty years. Cardiovasc Res (2000) 1.12
Angiographic assessment of prospectively determined non-invasive reperfusion indices in acute myocardial infarction. Heart (2000) 1.12
Markers of apoptosis in cardiovascular tissues: focus on Annexin V. Cardiovasc Res (2000) 1.10
Spontaneous coronary artery dissection: current insights and therapy. Neth Heart J (2008) 1.10
Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. J Cell Mol Med (2012) 1.08
Major achievements in cardiology in the past century: influence on Dutch cardiovascular medicine. Neth Heart J (2009) 1.07
Developmental changes in beta-adrenergic modulation of L-type Ca2+ channels in embryonic mouse heart. Circ Res (1996) 1.07
Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics (2006) 1.06
Assessment of LV ejection fraction using real-time 3D echocardiography in daily practice: direct comparison of the volumetric and speckle tracking methodologies to CMR. Neth Heart J (2014) 1.04
Cardiac remodeling after myocardial infarction is impaired in IGF-1 deficient mice. Cardiovasc Res (2001) 1.00
Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. Cell Mol Life Sci (2009) 1.00
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D. Neth Heart J (2012) 0.99
Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry). Neth Heart J (2015) 0.99
Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl Res (2013) 0.96
Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clin Genet (2006) 0.96
Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta (2012) 0.96
CT fractional flow reserve: the next level in non-invasive cardiac imaging. Neth Heart J (2012) 0.96
Risk scores for patients with chest pain: evaluation in the emergency department. Curr Cardiol Rev (2011) 0.93
Traumatic papillary muscle rupture. Ann Thorac Surg (2001) 0.93
Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol (2009) 0.93
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun (2006) 0.92
Journal metrics for the Netherlands Heart Journal. Neth Heart J (2011) 0.92
Multimodality infarct identification for optimal image-guided intramyocardial cell injections. Neth Heart J (2014) 0.92
Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. Panminerva Med (2010) 0.92
Bicuspid stenotic aortic valves: clinical characteristics and morphological assessment using MRI and echocardiography. Neth Heart J (2011) 0.92
A microplate assay for DNA damage determination (fast micromethod). Anal Biochem (1999) 0.91
Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol (Oxf) (2007) 0.91
Renal denervation: a new treatment option in resistant arterial hypertension. Neth Heart J (2013) 0.91
Infection after ICD implantation: operating room versus cardiac catheterisation laboratory. Neth Heart J (2009) 0.90
New and viable cells to replace lost and malfunctioning myocardial tissue. Minerva Cardioangiol (2004) 0.89
Coronary artery disease: arterial remodelling and clinical presentation. Heart (1999) 0.89
Somatic stem cells and cardiac repair: where is the science? Neth Heart J (2004) 0.89
Beta-blocker therapy in unstable severe heart failure, evidence or experience? Neth Heart J (2013) 0.89
Stem cell sources for cardiac regeneration. Panminerva Med (2008) 0.86
Electrocardiographic remodeling in patients paced for heart failure. Am J Cardiol (2000) 0.85
Effectiveness of a hospital-based vascular screening programme (SMART) for risk factor management in patients with established vascular disease or type 2 diabetes: a parallel-group comparative study. J Intern Med (2010) 0.84
Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. Cardiovasc Res (2003) 0.84
Expression of the smoothelin gene is mediated by alternative promoters. Cardiovasc Res (2002) 0.84
Diagnostic value of a heart-type fatty acid-binding protein (H-FABP) bedside test in suspected acute coronary syndrome in primary care. Int J Cardiol (2013) 0.83
Continuous-flow left ventricular assist device support in patients with advanced heart failure: points of interest for the daily management. Eur J Heart Fail (2012) 0.83
Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem (2007) 0.82
T cell apoptosis in human heart allografts: association with lack of co-stimulation? Am J Pathol (1998) 0.81
Stem cell therapy for end-stage heart failure: indispensable role for the cell? Curr Opin Organ Transplant (2009) 0.81
Netherlands Heart Journal: accepted into PubMed Central! Neth Heart J (2006) 0.81
Early mitral valve repair versus watchful waiting in patients with severe asymptomatic organic mitral regurgitation; rationale and design of the Dutch AMR trial, a multicenter, randomised trial. Neth Heart J (2012) 0.81
Wolff-Parkinson-white syndrome: a genetic disease? Circulation (2001) 0.81
Infective complications after transcatheter aortic valve implantation: results from a single centre. Neth Heart J (2012) 0.80
The human internal thoracic artery releases more nitric oxide in response to vascular endothelial growth factor than the human saphenous vein. J Thorac Cardiovasc Surg (2001) 0.80
Cyclosporin in cell therapy for cardiac regeneration. J Cardiovasc Transl Res (2014) 0.80
Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice. Genomics (2007) 0.79
Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med (2010) 0.78
Activation of MAP kinase signaling pathway in the mussel Mytilus galloprovincialis as biomarker of environmental pollution. Aquat Toxicol (2009) 0.78
Comparison of bioaccumulation and biomarker responses in Dreissena polymorpha and D. bugensis after exposure to resuspended sediments. Arch Environ Contam Toxicol (2012) 0.78
Does folate therapy reduce the risk of coronary restenosis? Neth Heart J (2007) 0.78
MAP kinase cell signaling pathway as biomarker of environmental pollution in the sponge Suberites domuncula. Ecotoxicology (2011) 0.78
Rationale of the REPARATOR study: A randomised trial with serial cardiac MRI follow-up testing the ability of atorvastatin to reduce reperfusion damage after primary PCI for acute MI. Neth Heart J (2006) 0.78
Ruptured aneurysm of the left sinus of Valsalva into the pericardium. Neth Heart J (2001) 0.78
Revascularization of patients with coronary artery disease: the interventional cardiologist's perspective. Ann Thorac Surg (1997) 0.78
Echocardiographic deformation imaging reveals preserved regional systolic function in endurance athletes with left ventricular hypertrophy. Br J Sports Med (2009) 0.78
Atrial dissection for atrial fibrillation: when, how much and where? J Am Coll Cardiol (1996) 0.78
Pacing Therapies in Congestive Heart Failure II study. Am J Cardiol (2000) 0.78
Aortic dissection, a complication during successful angioplasty of chronic total occlusion of the right coronary artery, was treated conservatively. Cardiovasc J Afr (2012) 0.77
Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension. Neth Heart J (2007) 0.77
Expression of a transgene encoding mutant p193/CUL7 preserves cardiac function and limits infarct expansion after myocardial infarction. Heart (2009) 0.77
BEta versus Gamma Utrecht Trial-Cypher (BEGUT-CYPHER): Is intracoronary brachytherapy still superior to drug-eluting stents? Neth Heart J (2004) 0.77
Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth J Med (1994) 0.76
Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease. Eur Heart J (2002) 0.76
Induction of apoptosis in mussel Mytilus galloprovincialis gills by model cytotoxic agents. Ecotoxicology (2011) 0.76
The tale of the three sisters. Neth Heart J (2010) 0.75
Regional differences in incidence of sudden cardiac death in the young. Neth J Med (2010) 0.75
One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. Neth Heart J (2010) 0.75
Methods in molecular cardiology: microarray technology. Neth Heart J (2003) 0.75